Abstract
No public abstract is available from the verified source records.
Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Allangba, Philippe Rey, Véronique Dorvaux, Marguerite Vignon, Virginie Roland, Réda Garidi, Jean‐Noel Bastie, Marie‐Lorraine Chretien, Sophie Godet, Lydia Montes, Brieuc Cherel, Anne Vekhoff, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez‐Olivier, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Sabrina Maheo, Anais Schavgoulidze, Pascal Godmer, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Stephanie Harel, Olivier Decaux, Karim Belhadj, Aurelie Gontier, Cyrille Touzeau, Philippe Moreau, Cyrille Hulin
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa2400712 · 2024
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant‐ineligible or transplant‐deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
10.1038/s41591-024-03485-7 · 2025
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant‐ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
10.1038/s41591-024-03050-2 · 2024
Use of daratumumab in high risk multiple myeloma: a meta‐analysis
10.1002/jha2.47 · 2020
Evaluation of daratumumab for the treatment of multiple myeloma in patients with high‐risk cytogenetic factors: a systematic review and meta‐analysis
10.1001/jamaoncol.2020.4338 · 2020
Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma
10.1200/jco.18.00776 · 2019
International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high‐risk multiple myeloma
10.1200/jco-24-01893 · 2025
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE‐MM3 and ‐MM4 trials
10.1182/blood.2022016782 · 2023
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
10.1182/blood.2020010439 · 2022
A DNA target‐enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
10.1038/bcj.2016.72 · 2016
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
10.1038/s41375-018-0037-9 · 2018
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
10.1016/s1470-2045(16)30206-6 · 2016
High‐risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next‐generation sequencing
10.1182/blood.2025029999 · 2026
Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta‐analysis
10.1001/jamaoncol.2016.3160 · 2017
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
10.1182/blood-2018-06-858613 · 2018
Measurable residual disease by next‐generation flow cytometry in multiple myeloma
10.1200/jco.19.01231 · 2020
Definition and clinical significance of the monoclonal gammopathy of undetermined significance‐like phenotype in patients with monoclonal gammopathies
10.1200/jco.22.01916 · 2023
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
10.1182/blood.2024026230 · 2025
Measurable residual disease‐guided therapy in newly diagnosed myeloma
10.1056/nejmoa2505133 · 2025
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa2312054 · 2024
No additional external references are available.